PMID- 22609068
OWN - NLM
STAT- MEDLINE
DCOM- 20140203
LR  - 20130610
IS  - 1522-9629 (Electronic)
IS  - 1094-5539 (Linking)
VI  - 26
IP  - 4
DP  - 2013 Aug
TI  - Obesity, expiratory flow limitation and asthma symptoms.
PG  - 438-43
LID - S1094-5539(12)00067-3 [pii]
LID - 10.1016/j.pupt.2012.05.004 [doi]
AB  - Obesity is associated with poor asthma control, but the reason for this is 
      unclear. Reduction in operating lung volume, as occurs in obesity, and 
      bronchoconstriction, as occurs in asthma, can increase expiratory flow limitation 
      during tidal breathing (EFLt), which may in turn increase respiratory symptoms. 
      The aim of this study was to determine the effect of obesity on EFLt at baseline 
      and after bronchoconstriction in non-asthmatic and asthmatic subjects, and to 
      determine the association between EFLt, and respiratory symptoms. Data from 
      previously published studies in non-asthmatic and asthmatic subjects were 
      reanalyzed using an index of EFLt derived from respiratory system reactance 
      measured by the forced oscillation technique. The analysis showed that during 
      bronchoconstriction both non-asthmatic and asthmatic obese individuals were more 
      likely to develop EFLt than non-obese subjects, despite similar changes in FEV1. 
      Furthermore the index of EFLt was a significant determinant of the severity of 
      breathlessness during challenge in non-asthmatic subjects, and of asthma symptom 
      control in asthmatic subjects following anti-inflammatory treatment. These 
      studies suggest that the combination of bronchoconstriction and low resting lung 
      volume increase the risk of EFLt, and that this altered response to 
      bronchoconstriction may increase the severity of symptoms and lead to worse 
      asthma control.
CI  - Copyright (c) 2012 Elsevier Ltd. All rights reserved.
FAU - Mahadev, Sriram
AU  - Mahadev S
AD  - Woolcock Institute of Medical Research, 431 Glebe Pt Rd., Glebe, NSW 2037, 
      Australia. smahadev@med.usyd.edu.au
FAU - Farah, Claude S
AU  - Farah CS
FAU - King, Gregory G
AU  - King GG
FAU - Salome, Cheryl M
AU  - Salome CM
LA  - eng
PT  - Journal Article
DEP - 20120515
PL  - England
TA  - Pulm Pharmacol Ther
JT  - Pulmonary pharmacology & therapeutics
JID - 9715279
RN  - 0 (Anti-Inflammatory Agents)
SB  - IM
MH  - Adult
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Asthma/drug therapy/*physiopathology
MH  - Bronchoconstriction/drug effects
MH  - Case-Control Studies
MH  - Forced Expiratory Volume
MH  - Humans
MH  - Maximal Expiratory Flow Rate
MH  - Middle Aged
MH  - Obesity/*physiopathology
MH  - Retrospective Studies
MH  - Severity of Illness Index
EDAT- 2012/05/23 06:00
MHDA- 2014/02/04 06:00
CRDT- 2012/05/22 06:00
PHST- 2012/01/13 00:00 [received]
PHST- 2012/03/30 00:00 [revised]
PHST- 2012/05/07 00:00 [accepted]
PHST- 2012/05/22 06:00 [entrez]
PHST- 2012/05/23 06:00 [pubmed]
PHST- 2014/02/04 06:00 [medline]
AID - S1094-5539(12)00067-3 [pii]
AID - 10.1016/j.pupt.2012.05.004 [doi]
PST - ppublish
SO  - Pulm Pharmacol Ther. 2013 Aug;26(4):438-43. doi: 10.1016/j.pupt.2012.05.004. Epub 
      2012 May 15.